Lineage Cell Therapeutics Expands Pipeline with New Corneal Endothelial Disease Program

On March 24, 2026, Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology firm, announced the launch of its new cell therapy program aimed at addressing corneal endothelial disease. This innovative initiative, named COR1, is currently in preclinical development and signals the company’s commitment to enhancing its cell transplant pipeline.

Corneal endothelial disease is a progressive condition that primarily affects the inner layer of the cornea, leading to cell death, corneal swelling, and ultimately, vision loss. The most common forms of this disease include Fuchs Endothelial Corneal Dystrophy (FECD) and Bullous Keratopathy. With an alarming global statistic indicating only one donor cornea available for every 70 diseased eyes, the need for effective and accessible treatments has never been more critical.

Brian M. Culley, CEO of Lineage, emphasized the urgency of addressing this medical need, stating, “Millions of people are candidates for corneal transplants, for which today there is only one donor for every 70 diseased eyes globally.” This stark reality highlights the company’s opportunity to revolutionize treatment options through its new COR1 program.

Lineage’s proprietary cell manufacturing and expansion platform, AlloSCOPE™ (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent cell Engineering), underpins the COR1 initiative. This innovative platform has enabled Lineage to produce “off the shelf” corneal endothelial cells that meet essential identity, morphological, and functional characteristics necessary for further development.

Culley noted the potential of AlloSCOPE to provide a consistent and reliable source of corneal endothelial cells, stating, “We believe we are well positioned to produce and provide a consistent and ‘off-the-shelf’ allogeneic source of CEnC’s.” The platform’s scalability and cost-effectiveness are expected to significantly reduce the barriers associated with traditional cadaveric sources of CEnCs, which are often limited by the low availability of organ donors and inconsistent quality.

Fuchs endothelial corneal dystrophy, the leading indication for corneal transplantation globally, affects approximately 7.33% of adults over 30 years of age. As the patient population is projected to grow from around 300 million in 2020 to 415 million by 2050, the demand for effective therapies is set to surge. Lineage’s COR1 program aims to tap into a substantial addressable market, estimated at 2-6 million patients in the United States alone and around 16 million in Europe.

The implications of successful CEnC therapy could be profound. Unlike traditional corneal transplants, which are invasive and require extensive surgical procedures, cell therapy for FECD is minimally invasive. Treatment involves injecting the cells into the anterior chamber of the eye, allowing for a quicker recovery and potentially improved patient outcomes.

Lineage is committed to advancing the COR1 program into preclinical testing, with plans to provide developmental updates as they arise. The company’s strategic use of its AlloSCOPE "5D" manufacturing process is expected to facilitate large-scale production, further reducing costs and enhancing the availability of the treatment.

Culley remarked on the exciting opportunities ahead, underscoring the importance of clinical and regulatory precedents that have already been established in Japan, where CEnC therapy from cadaveric sources has received approval for treating corneal endothelial disease. This existing framework bolsters Lineage’s confidence in developing a more consistent and cost-effective product to address the global shortage of donor cells.

Lineage Cell Therapeutics is poised to make significant strides in the treatment of corneal endothelial disease with the launch of its COR1 program. By leveraging its advanced AlloSCOPE platform and addressing a critical gap in the market, the company aims to provide innovative solutions that could transform patient care and alleviate the burdens associated with corneal transplants. As Lineage progresses through the preclinical phase, the biotech landscape will be keenly watching for developments that could reshape the treatment of corneal diseases worldwide.